Alpha Emitters Market Industry Analysis, Opportunities, Technology, Demand, Top Players and Growth Forecast
Radionuclides with alpha emitters plays an important role in treating cancers in the field of therapeutic radiopharmaceuticals. Some properties such as short range and deposited energy in unit length of pathway augment the effect of alpha particle in destroying the DNA of cancer cells. Therefore, recognizing this capacity involves more investigations over the biological effect of these particles on human body. Properties of alpha emitters has led to exert profound differences between this field and other fields of nuclear medicine. Due to their short range and high LET (deposit energy in unit length of their pathway), alpha particles have remarkably been considered into medical research.
To know the scope of our report get a sample on https://www.axiommrc.com/request-for-sample/1717-alpha-emitters-market-report
Alpha Emitters Market Trends
Targeted anticancer or alpha therapy (TAT)
is gaining popularity with the swelling prevalence of cancer and cardiovascular
diseases. Businesses are now increasingly aware of the potential benefits of
targeted therapies to treat several chronic ailments. Additionally, radio
immunotherapy with short-ranged and high-efficiency?-particles is a striking
and promising treatment approach.
Previously, more effective therapeutic nuclear medicines have been launched, which have shown positive results for the treatment of various types of cancer. For instance, the launch of Xofigo (Radium-223) by Bayer for the treatment of prostate cancer and the launch of Lutathera (Lutetium-177) for the treatment of neuroblastoma and synovitis has created growth opportunities for the therapeutic nuclear medicines market. In addition, the launch of these products has boosted the demand for therapeutic nuclear medicines among patients and physicians as well as opened the door for the other pharmaceutical manufacturers to launch more efficient therapeutic nuclear medicines.
Alpha Emitters Market Outlook
Increase in awareness of the potential
benefits of targeted alpha emitter and high number of patients with various
types of cancers such as ovarian cancer, pancreatic cancer, lymphoma, and
melanoma are likely to augment market growth. In addition, increasing use of
targeted anticancer or alpha therapy (TAT) in the treatment of cancer and alpha
particles has an advantage in targeted therapy because of their exceptionally
high cell-killing ability. Ovarian cancer uses radioimmunotherapy as locally
injected adjuvant therapy. Trials have evaluated the practice of complete
abdominal or moving-strip external-beam radiotherapy (EBRT) or non-specific
i.p. radiotherapy, with colloid preparations of Au-198 or P-32 as adjuvant
therapies. Furthermore, a recent Phase I clinical trial involving At-211-MX35 F
(ab) showed significant efficacy, as therapeutic doses reached their targets in
patients with ovarian cancer.
Alpha Emitters Market Covid-19 Impact
The healthcare industry has observed a relatively slow growth due to the COVID-19 pandemic unlike other industries. Numerous therapeutic regimens are being followed across the world in efforts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line emphases to use antiviral drugs used in the disease management of HIV. Both these approaches have poured demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be controlled upon.
Alpha Emitters Market Regional Trends
The global market is studied for the key regions such as, North America, Europe, Asia Pacific and Rest of the World. North America comprises of U.S., Canada and Mexico. Whereas, Europe covers UK, France, Germany, Italy, Spain and Rest of Europe. The key countries included under Asia Pacific are China, India, Japan and Rest of Asia Pacific. The Rest of the world include Latin America and Middle East & Africa. North America was a lucrative region for the alpha emitters market in 2019. North America currently dominates the alpha emitter market, and it is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the fact that the increase in cardiac and neurological chronic diseases. For instance, 223RaCl2 (Xofigo) is the first alpha-emitting radioisotope to gain registration in the United States for palliative therapy of prostate cancer bone metastases through indirect physiological targeting.
Alpha Emitters Market Segmental Highlights
The report analyses the global alpha emitters market based on radionuclide type, medical application, end user and geography. Various radionuclide type studied are segmented into Actinium (Ac-225), Astatine (At-211), Bismuth (Bi -213), Bismuth (Bi-212), Lead (Pb-212), Radium (Ra-223) and Terbium (Tb-149). Alpha emitter offers many advantages when compared to beta emitters and photon therapy, thus making it an increasingly favoured mode of treatment. As a result, this has caught the attention of key companies interested in capitalizing the market potential.
The medical application segment is categorized into prostate cancer, bone metastases, ovarian cancer, pancreatic cancer, endocrine tumors and others. Alpha emitter therapy holds a great promise when compared to chemotherapy as targeted alpha therapy allows easy discrimination between the healthy cells and cancer cells, and hence are effectively used for treatment of cancers including ovarian cancer, pancreatic cancer etc. Furthermore, the major end users considered in the study are hospitals, clinics and research laboratories.
Alpha Emitters Market Key Players
The key companies in the alpha emitters
market are Actinium Pharmaceuticals, Alpha Tau Medical, Bayer AG, IBA
RadioPharma Solutions, NTP Radioisotopes, Plexus NSD, Triad Isotopes, Telix
Pharmaceuticals Ltd, RadioMedix Inc. and Fusion Pharmaceuticals. Moreover, the
leading radiopharmaceutical manufacturers are collaborating with hospitals and
cancer research institutes for the sale of their products, which has increased
the acceptance of therapeutic nuclear medicines. For instance, in January 2020,
Actinium Pharmaceuticals, Inc., entered into an agreement with the University
of California to utilize Actinium's Antibody Radiation-Conjugate or ARC
apamistamab-I-131 for targeted conditioning and replace the chemotherapy
conditioning being used in an ongoing Phase 1/2 stem cell gene therapy clinical
trial. In the trial, patients with relapsed or refractory HIV-related lymphoma
are being treated with autologous stem cell gene therapy.
Buy
now Alpha Emitters Market Report https://www.axiommrc.com/buy_now/1717-alpha-emitters-market-report
About Us:
Axiom Market Research & Consulting™ is a full-service market research and data analytics company providing key market intelligence to global companies to take informed business decisions pertaining to their marketing strategy, investments, new product launches, market competition, consumer or end users, social media trends etc.
Axiom Market Research & Consulting™ offers market research services such as syndicated market research, custom market research, business consulting, and consumer/end user surveys. Under Business to Consumer (B2C) market research offerings, Axiom MRC assists its clients in finding quantitative information/preferences of its brands and services such as, awareness, usages, satisfaction, tracking, ethnicity etc. Axiom MRC offers data collection services through online surveys, social media, data processing and interpretation.
Axiom MRC with its experienced team of research and data analysts, has delivered more than 5000+ Market Research Projects, 3800+ Data Analytics Projects, 1200+ Business Support Projects and has a 800+ Global Client Base. Axiom Market Research & Consulting™ aims to become the preferred market research and data analytics company by providing key market intelligence solutions for client’s business growth.
Contact Us:
Axiom Market Research
& Consulting™
3 Germay Dr. Ste
4 - 4666
Wilmington DE
19804
U.S.:- + 1 (845)
875-9786
U.K.:- + 44 (0)
20 3286 9707
Email: sales@axiommrc.com
Website: https://www.axiommrc.com/
Blog: https://industrywatch24.com/
Follow On
LinkedIn: https://www.linkedin.com/company/axiom-market-research-and-consulting/
Twitter: https://twitter.com/AxiommrcCom
Comments
Post a Comment